Syncore Biotechnology Co., Ltd. Reports Earnings Results for the Third Quarter Ended September 30, 2018
November 11, 2018 at 07:52 pm
Share
Syncore Biotechnology Co. Ltd. announced earnings results for the third quarter ended September 30, 2018. For the third quarter, the company announced sales was TWD 2.007 million compared to TWD 2.047 million a year ago. Operating loss was TWD 81.326 million compared to TWD 65.838 million a year ago. Net loss was TWD 80.816 million compared to TWD 64.284 million a year ago. Basic loss per share was TWD 1.02 compared to TWD 0.92 a year ago. For the nine months, sales was TWD 5.778 million compared to TWD 6.157 million a year ago. Operating loss was TWD 203.529 million compared to TWD 192.622 million a year ago. Net loss was TWD 201.874 million compared to TWD 190.324 million a year ago. Basic loss per share was TWD 2.75 compared to TWD 2.72 a year ago.
SynCore Biotechnology Co.,Ltd is a Taiwan-based company principally engaged in the research, development, production and sales of therapeutic drugs. The Company's main product is SB03 Veregen. The Company is also involved in research, development and clinical trials of the injection-type anticancer drug, SB01 and the oral anticancer drug, SB01. The Company distributes its products mainly in domestic market.